By Stephen Nakrosis

The Janssen Pharmaceutical Companies of Johnson & Johnson presented long-term data from its Phase 3 VOYAGE 1 clinical trial of Tremfya, a treatment for adult patients with moderate to severe plaque psoriasis.

The data, being presented at the 39th Fall Clinical Dermatology Conference, studied patients receiving Tremfya, or guselkumab, from a group initially randomized to Tremfya or to placebo with crossover to Tremfya at week 16. Janssen said 82% achieved at least a 90% improvement in the Psoriasis Area Severity Index.

At 204 weeks, patients receiving Tremfya continued to show maintained PASI 90 and an Investigator's Global Assessment score of cleared or minimal disease, the company said.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

October 17, 2019 16:54 ET (20:54 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Johnson and Johnson Charts.